Synergistic effect of urinary bladder carcinogenesis in rats treated with N-butyl-n-(4-hydroxybutyl)nitrosamine, N-(4-(5-nitro-2-furyl)-2-thiazolyl)formamide,N-2-fluorenylacetamide, and 3,3'-dichlorobenzidine.
D015101:3,3'-Dichlorobenzidine; D000818:Animals; D001560:Benzidines; D002085:Butylhydroxybutylnitrosamine; D002273:Carcinogens; D002295:Carcinoma, Transitional Cell / Q000139:chemically induced* / Q000473:pathology; D004357:Drug Synergism; D005234:Fatty Liver / Q000139:chemically induced / Q000473:pathology; D005559:Formamides; D008099:Liver / Q000473:pathology; D008297:Male; D009374:Neoplasms, Experimental; D009602:Nitrosamines; D010212:Papilloma / Q000139:chemically induced* / Q000473:pathology; D011230:Precancerous Conditions / Q000139:chemically induced / Q000473:pathology; D051381:Rats; D001743:Urinary Bladder / Q000473:pathology; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced* / Q000473:pathology
D001560:Benzidines; D002273:Carcinogens; D005559:Formamides; D009602:Nitrosamines; D015101:3,3'-Dichlorobenzidine; D002085:Butylhydroxybutylnitrosamine